ATLANTA, GA – – (Globe Newswire – August 17, 2026) – – A shareholder class action lawsuit has been filed against Aardvark Therapeutics, Inc. (“Aardvark”) (NASDAQ: AARD). The lawsuit alleges that Defendants, in Aardvark’s Registration Statement and throughout the Class Period, made false and misleading statements and/or failed to disclose material adverse facts, including allegations that: (i) ARD-101 was less safe than Defendants had led investors to believe; and (ii) accordingly, ARD-101’s clinical, regulatory, and commercial prospects were overstated.

 If you purchased Aardvark shares between February 13, 2025 and May 14, 2026, and experienced a loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at cholzer@holzerlaw.com, by toll-free telephone at (888) 508-6832, or by visiting the firm’s website at www.holzerlaw.com/case/aardvark-therapeutics/ for more information.

The deadline to ask the court to be appointed lead plaintiff in the case is October 13, 2026.